Abstract
Purpose To review treatment strategies in neovascular age-related macular degeneration (ARMD).
Methods Medline and Embase search. Results Age-related macular degeneration (ARMD) is the commonest cause of blindness in the developed world in individuals over 50 years of age. ARMD may lead to loss of vision by atrophy of the retinal pigment epithelium or by the development of choroidal neovascular membranes (CNVM) under the macula, which leak serous fluid and blood and ultimately cause a blinding disciform scar. Treatment options currently being investigated fall into three main approaches: elimination of the CNVM from the subfoveal area (by laser or surgery), modification of the CNVM (by laser, radiotherapy or chemotherapeutic agents) or lastly prevention of the formation of CNVM (by laser prophylaxis, diet or gene targeting). Whilst almost no therapy restores normal visual acuity, any significant visual improvement over the natural history may be regarded as beneficial.
Conclusions Both the current and immediate future potential therapies for choroidal neovascularisation in ARMD require considerable advances to be made before they will make any impact on blindness caused by ARMD. Of the current treatments none are curative and the treatment benefits are small. There is an urgent need for new therapies.
Similar content being viewed by others
Article PDF
References
Bressler NM, Bressler SB, Fine SL . Age-related macular degeneration. Surv Ophthalmol 1988;32:375–413.
Klein R, Klein BEK, Linton KLP . Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933–43.
Margherio RR, Margherio AR, DeSantis ME . Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000;20:325–30.
Brown GC, Brown MM, Sharma S . Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:127–33.
Brown GC, Sharma S, Brown MM, Kistler J . Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47–51.
Brown MM, Brown GC, Sharma S, Garrett S . Evidence-based medicine, utilities and quality of life. Curr Opin Ophthalmol 1999;10:211–6.
Chong NHV, Bird AC . Alternative therapies in exudative age related macular degeneration. Br J Ophthalmol 1998;82:1441–3.
Moorfields Macula Study Group. Treatment of senile disciform macular degeneration: a single blind randomised trial by argon laser photocoagulation. Br J Ophthalmol 1982;66:746–53.
Macula Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after five years: results from randomized clinical trials. Arch Ophthalmol 1991;109:1109–14.
Macula Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991;109:1232–41.
Macula Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macula degeneration: update findings from two clinical trials. Arch Ophthalmol 1993;111:1200–9.
Macula Photocoagulation Study Group. Laser photocoagulation of juxtafoveal choroidal neovascularization: five-year results of randomized clinical trials. Arch Ophthalmol 1994;112:500–9.
Macula Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480–8.
Brown GC, Brown MM, Sharma S, Brown H, Tasman W . Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000;107:1374–80.
Algvere PV, Berglin L, Gouras P, Sheng Y . Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol 1994;232:707–16.
Rezai KA, Kohen L, Wiedemann P, Heimann K . Iris pigment epithelium transplantation. Graefes Arch Clin Exp Ophthalmol 1997;232:558–62.
Ciulla TA, Danis RP, Harris A . Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998;43:134–46.
Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384–96.
Scheider A, Gundisch O, Kampik A . Surgical extraction of subfoveal choroidal new vessels and submacular haemorrhage in age-related macular degeneration: results of a prospective study. Graefes Arch Clin Exp Ophthalmol 1999;237:10–5.
Humayun MS, Juan ED, Cerro MD, et al. Human neural retinal transplantation. Invest Ophthalmol Vis Sci 2000;41:3100–6.
Thumann G, Aisenbrey S, Schraermeyer U, et al. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. Arch Ophthalmol 2000;118:1350–5.
Submacular Surgery Trials. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. I. Ophthalmic outcomes. Submacular surgery trials pilot study report number 1(2). Am J Ophthalmol 2000;130:387–407.
Submacular Surgery Trials. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. II. Quality of life outcomes. Submacular surgery trials pilot study report number 2. Am J Ophthalmol 2000;130:408–18.
Eckardt C, Eckardt U, Conrad HG . Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313–25.
Lewis H, Kaiser PK, Lewis S, Estafanous M . Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am J Ophthalmol 1999;128:135–46.
Pieramici DJ, Juan ED, Fujii GY, et al. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2000;130:419–28.
Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000;130:751–62.
Flower RW, Synder WJ . Expanded hypothesis on the mechanism of photodynamic therapy action on choroidal neovascularization. Retina 1999;19:365–9.
Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol 2001;119:198–207.
Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials: TAP report 1. Arch Ophthalmol 1999;117:1329–45.
Mainster MA, Reichel E . Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis and heat shock proteins. Ophthalmic Surg Lasers 2000;31:359–73.
Newsom RS, McAlister JC, Saeed M, McHugh JD . Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br J Ophthalmol 2001;85:173–8.
Arlett C, Harcourt F . Survey of radiosensitivity in a variety of human cell strains. Cancer Res 1980;40:926–32.
Rheinhold HS, Buisman GH . Radiosensitivity of capillary endothelium. Br J Radiol 1973;46:54–7.
Archer DB, Amoaku WMK, Gardiner TA . Radiation retinopathy: clinical, histological and ultrastructural correlation. Eye 1991;5:239–51.
Chakravarthy U, Gardiner TA, Archer DB, Maguire CJF . A light microscopic and autoradiographic study of irradiated ocular wounds. Cur Eye Res 1989;8:337–47.
Verheij M, Koomen GC, Mourik JAV, Dewitt L . Radiation reduced cyclooxygenase activity in cultured human endothelial cells at low doses. Prostaglandins 1994;48:351–66.
Chakravarthy U, Housten RF, Archer DB . Treatment of age-related subfoveal neovascular membrane by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265–73.
Chakravarthy U . Radiotherapy for choroidal neovascularisastion of age-related macular degeneration: a fresh perspective. Eye 2000;14:151–4.
Kobayashi H, Kobayashi K . Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 2000;130:617–35.
Marcus DM, Sheils WC, Johnson MH, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial Arch Ophthalmol 2001;119:171-80.External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial Arch Ophthalmol 2001;119:171–80.
Bergink GJ, Hoyng CB, Maazen RWVD, Vingerling JR, Daal WAJV, Deutman AF . A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthamol 1998;236:321–5.
Char DH, Irvine AI, Posner MD, Quivey J, Phillips TL, Kroll S . Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 1999;127:574–8.
Radiation Therapy for Age-related Macular Degeneration (RAD) Study Group. A prospective double-masked trial on radiation therapy for neovascular age-related macular degeneration. Ophthalmology 1999;106:2239–47.
Pharmacological Therapy for Macular Degeneration Study Group. Interferon-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997;115:865–72.
Thomas MA, Ibanez HE . Interferon alpha-2 in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 1993;115:563–8.
D'Amato RJ, Loughan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–5.
Danis RP, Ciulla TA, Pratt LM, Anliker W . Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244–50.
Penfold P, Gyory J, Hunyor A, Billson F . Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust N Z J Ophthalmol 1995;23:293–8.
Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA . Exudative macular degeneration and intravitreal triamcinolone: 18 month follow-up. Aust N Z J Ophthalmol 1998;26;277–81.
Lanchoney DM, Maguire MG, Fine SL . A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration: comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol 1998;116:1045–52.
Guymer RH, Gross-Jendroska M, Owens SL, Bird AC, Fitzke FW . Laser treatment in subjects with high-risk clinical features of age-related macular degeneration: posterior pole appearance and retinal function. Arch Ophthalmol 1997;115:595–603.
Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen: short-term effects seen in a pilot randomized clinical trial. Ophthalmology 1998;105:11–23.
Choroidal Neovascularization Prevention Trial Research Group. Laser-induced drusen reduction improves visual function at 1 year. Ophthalmology 1999;106:1367–73.
Olk RJ, Friberg TR, Stickney KL, et al. Therapeutic benefits of infrared (810 nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 1999;106:2082–90.
Bone RA, Landrum JT, Dixon Z, Chen Y, Llerena CM . Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp Eye Res 2000;71:239–45.
Evans JR . Antioxidant vitamin and mineral supplements for age-related macular degeneration (Cochrane review). The Cochrane Library, Oxford: Update Software, 2001:vol 1.
Wright AF . Gene therapy for the eye. Br J Ophthalmol 1997;81:620–63.
Murata T, Cui J, Taba KE . The possiblity of gene therapy for the treatment of choroidal neovascularization. Ophthalmology 2000;107:1364–73.
Author information
Authors and Affiliations
Corresponding author
Additional information
Proprietary interest: None
Rights and permissions
About this article
Cite this article
Votruba, M., Gregor, Z. Neovascular age-related macular degeneration: Present and future treatment options. Eye 15, 424–429 (2001). https://doi.org/10.1038/eye.2001.147
Issue Date:
DOI: https://doi.org/10.1038/eye.2001.147
This article is cited by
-
Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease
Angiogenesis (2017)
-
Management of significant reactivation of old disciform scars in wet Age-Related Macular Degeneration
BMC Ophthalmology (2014)
-
Confocal scanning laser ophthalmoscope in the retromode imaging modality in exudative age-related macular degeneration
Graefe's Archive for Clinical and Experimental Ophthalmology (2013)
-
The end of submacular surgery for age-related macular degeneration? A meta-analysis
Graefe's Archive for Clinical and Experimental Ophthalmology (2007)
-
The local cone and rod system function in early age-related macular degeneration
Documenta Ophthalmologica (2004)